- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02853565
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Study Overview
Detailed Description
CAN008 is a glycosylated fusion protein consisting of the extracellular domain of human CD95 (APO-1/Fas) and the Fc domain of human IgG1. CAN008 blocks the interaction between CD95 and its cognate ligand CD95L. The target of CAN008 is the inhibition of CD95L. CD95L is expressed in glioblastoma whose cells are resistant to CD95-mediated apoptosis. CD95L was shown to be a crucial trigger in invasion and migration of tumor cells and neutralizing CD95L abolishes the invasive capacity of glioblastoma cells.
The purpose of the study is:
- To describe the toxicity associated with this regimen in adult patients with newly diagnosed glioblastoma multiforme.
- To determine the duration of disease free survival and overall survival associated with this therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
Taipei, Taiwan, 100
- Chang Gung Memorial Hospital, Linkou
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosed and histologically confirmed glioblastoma multiforme
- Tumor must be surgically accessible and tissue must be available
- Age ≥ 20 years and < 75 years
- Life expectancy ≥ 6 months
- Baseline MRI images must be done within 2 days after surgery
- Patients must have a Karnofsky performances score ≥ 60 prior to treatment.
- Patients must not have received prior cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy for brain tumors.
- Adequate hematologic (absolute neutrophil count (ANC) ≥ 1.5x109/L, platelet count ≥ 100x109/L, hemoglobin ≥ 10 g/dL ), renal (creatinine ≤ 1.25xULN ), and hepatic function (total bilirubin ≤ 1.5xULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5xULN)
- Women with childbearing potential must have a negative serum pregnancy test less than 7 days prior to the first dose of study drug.
- Both men and women of reproductive potential agree to use approved contraception, such as condom and placement of an intrauterine device (IUD), during the study and until 3 months after the discontinuation of study treatment.
- Willing and able to comply with the protocol as judged by the investigator
- Patients must provide written consent
Exclusion Criteria:
- Any prior chemotherapy (including carmustine-containing wafers) or immunotherapy (including vaccine therapy )
- Any prior radiotherapy to the brain
- Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial
- Any contraindication to TMZ listed in the local label
- Low-grade astrocytoma
- Unable to undergo MRI
- Past medical history of disease with poor prognosis according to the judgment of the Investigator
- HIV infection
- Patients with positive anti-HCV
- Patients with positive HbsAG who received any related treatment within the past 6 months
- Patients suffering from hereditary fructose intolerance (HFI).
- Patients receive any investigational agent(s) or device(s) within 30 days prior to entering the study
- Known coronary artery disease, significant arrhythmias or severe congestive heart failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CAN008
CAN008 administered as a 30 min intravenous infusion once a week until disease progression or unacceptable toxicity.
|
The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: up to 2 years
|
The safety assessment will include safety laboratory (clinical chemistry, hematology, urinalysis), physical exam, vital signs and 12-lead ECG (QT prolongation).
An AE can be any unfavourable and unintended sign, symptom, or disease temporarily associated with the use of a medicinal product, whether or not is considered to be related to the medicinal product.
Pre-existing conditions worsen during a study are also to be reported as AEs.
Furthermore, any side effects potentially related to the CAN008 treatment will be evaluated.
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended Dose for Phase II [RP2D] measured by the Maximum Tolerated Dose [MTD] or the Maximum Administered Dose [MAD]
Time Frame: up to 2 years
|
The RP2D will be determined based on the assessment of the observed toxicities, the maximum tolerated dose (MTD) or the maximum administered dose (MAD), and the overall safety profile of CAN008.
|
up to 2 years
|
PK profile measured by CAN008 serum concentrations
Time Frame: up to 2 years
|
CAN008 serum concentrations will be determined.
|
up to 2 years
|
PK profile measured by Maximum Plasma Concentration [Cmax]
Time Frame: up to 2 years
|
Maximum Plasma Concentration [Cmax] will be determined.
|
up to 2 years
|
PK profile measured by Area Under the Curve [AUC]
Time Frame: up to 2 years
|
Area Under the Curve [AUC] will be determined.
|
up to 2 years
|
Preliminary efficacy (Progression Free Survival after 6 months [PFS6])
Time Frame: up to 2 years
|
PFS is defined as the time from date of randomization to the date of the event, which is the first radiologically documented disease progression (per local investigator assessment according to Response Assessment in Neuro-Oncology (RANO) criteria) or death due to any cause.
For the primary analysis, progression-free survival after 6 months (PFS6) is defined as the crude rate of patients confirmed to be free of progression at 6 months after randomization with respect to the number of randomized and exposed patients in the respective treatment arm.
|
up to 2 years
|
Preliminary efficacy (Overall Survival [OS])
Time Frame: up to 2 years
|
Overall survival (OS) is defined as the time from the first dose of CAN008 to death.
|
up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ying Xu, MD, CANbridge Life Sciences Ltd.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAN-B1-008-L-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
University of UtahWithdrawnGlioblastoma Multiforme (GBM)United States
-
Sunnybrook Health Sciences CentreRecruitingGlioblastoma Multiforme, AdultCanada
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina
-
Polaris GroupRecruitingGlioblastoma Multiforme (GBM)Taiwan
-
University of IowaEisai Inc.TerminatedPrimary Glioblastoma MultiformeUnited States
Clinical Trials on CAN008
-
CANbridge Life Sciences Ltd.Unknown
-
CANbridge Life Sciences Ltd.Recruiting